Holen Sie sich die Stockscreener-App
2.28
16.92%
0.33
Vorhandelsmarkt:
2.38
0.10
+4.39%
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
Why Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma Application And What's Next - simplywall.st
Mass. biotech company to lay off 63 employees after FDA rejects cancer drug for 2nd time - MassLive
Replimune Group FY2026 EPS Estimate Lifted by HC Wainwright - MarketBeat
J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer - BioSpace
Replimune Group, Inc. Cash Ratio | REPL - MLQ.ai
Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma BLA Over Trial Design Concerns - Yahoo Finance
REPL Slides After Insider Filings Spark Trader Caution - StocksToTrade
FDA Rejection Sparks Questions On Replimune Drug Approval Path - Sahm
Replimune plunges after FDA rejects skin cancer drug again - MSN
Jefferies downgrades Replimune Group (REPL) - MSN
Massachussetts Biotech Co. Faces Major Melanoma Drug Setback - Streetwise Reports
Wedbush downgrades Replimune Group (REPL) - MSN
MA Biotech Co. Downgraded to Sell After Second FDA CRL for RP-1 Melanoma BLA - Streetwise Reports
REPL Downgraded by JP Morgan -- Rating Changed to Underweight - GuruFocus
Recon: FDA denies Replimune’s cancer drug over trial issues; Revolution’s cancer pill boosts survival in Phase 3 trial - RAPS.org
Fastenal, Replimune Group, Children's Place and other big stocks moving lower in Monday's pre-market session - MSN
Replimune Plans Layoffs After FDA Rejects Cancer Therapy. The Stock Hits an All-Time Low. - Barron's
REPL Downgraded by Cantor Fitzgerald -- Rating Changed to Neutra - GuruFocus
Replimune plunges after second FDA setback for melanoma therapy; analysts turn bearish - MSN
REPL Downgraded by Wedbush -- Price Target Lowered to $2.00 - GuruFocus
REPL Downgraded by Leerink Partners -- Price Target Lowered to $2.00 - GuruFocus
Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%. -- Barrons.com - Moomoo
REPL Downgraded by Jefferies -- Price Target Lowered to $2.00 - GuruFocus
Replimune Receives FDA Complete Response Letter for RP1 Biologics License Application in Advanced Melanoma, Plans Major Cutbacks - Minichart
Replimune Group (REPL) Faces Downgrades After FDA Rejects Melano - GuruFocus
Replimune Shares Plummet to All-Time Low as FDA Rejection Muddies Path Forward - marketscreener.com
FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment - Pharmaceutical Executive
Replimune Receives Second CRL for RP1 With Nivolumab for Treatment of Advanced Melanoma - Pharmacy Times
Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes - Zacks Investment Research
Street sours on Replimune as stock hits all-time low on melanoma drug rejection - Seeking Alpha
Replimune’s RP1 setback deepens after second FDA rejection - The Pharma Letter
REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays - MSN
Cantor Fitzgerald Reaffirms Neutral Rating for Replimune Group (NASDAQ:REPL) - MarketBeat
Replimune Group REPL Plunges After FDA Melanoma Rejection - StocksToTrade
Biggest stock movers Monday: REPL, GS, LEG and more (NYSE:GS) - Seeking Alpha
Replimune Group (NASDAQ:REPL) Lowered to "Underperform" Rating by BMO Capital Markets - MarketBeat
REPL Downgraded by HC Wainwright & Co. -- Rating Changed to Sell - GuruFocus
Pharmalittle: We're reading about a pancreatic cancer pill, FDA rejecting a Replimune drug again, and more - statnews.com
This NXP Semiconductors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Replimune Group (NASDAQ:REPL) Earns "Market Perform" Rating from Leerink Partners - MarketBeat
Replimune Group (NASDAQ:REPL) Receives "Neutral" Rating from Wedbush - MarketBeat
Replimune Group's (REPL) "Hold" Rating Reiterated at Jefferies Financial Group - MarketBeat
JPMorgan Chase & Co. Reaffirms Underweight Rating for Replimune Group (NASDAQ:REPL) - MarketBeat
FDA issues complete response letter to Replimune’s RP1 for melanoma - Pharmaceutical Technology
Replimune Group (NASDAQ:REPL) Given Sell Rating at HC Wainwright - MarketBeat
Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Sess - Benzinga
US Premarket Movers: Baker Hughes, Goldman, Leggett, Replimune - Bloomberg.com
Replimune Group, Inc. Shareholders Are Encouraged to Reach - GlobeNewswire
Piper Sandler Downgrades Replimune to Neutral From Overweight, Adjusts Price Target to $4 From $14 - marketscreener.com
Replimune melanoma therapy rejected by FDA, shares plunge - Proactive financial news
BMO Capital Downgrades Replimune to Underperform From Market Perform, Adjusts PT to $1 From $11 - marketscreener.com
JPMorgan Downgrades Replimune Group to Underweight From Neutral, $10 Price Target - marketscreener.com
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
Replimune (REPL) Shares Plummet After FDA Rejects Melanoma Treat - GuruFocus
Replimune receives second FDA Complete Response Letter for RP1 BLA, plans workforce and manufacturing cuts - TradingView — Track All Markets
Jefferies cuts Replimune stock rating on regulatory uncertainty By Investing.com - Investing.com South Africa
Replimune sinks 57% on second FDA rejection of melanoma drug; stock downgraded - Investing.com Canada
Jefferies cuts Replimune stock rating on regulatory uncertainty - Investing.com UK
BMO downgrades Replimune stock on FDA rejection concerns - Investing.com UK
BMO downgrades Replimune stock on FDA rejection concerns By Investing.com - Investing.com Canada
FDA hands another rejection to Replimune's melanoma therapy - pharmaphorum
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):